Anavex Life Sciences Corp.
AVXLHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, Anavex Life Sciences Corp. (AVXL) is listed under Biotechnology. The company carries a $123.3M market cap, placing it firmly in the micro-cap category. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer.
Market Cap
$123.3M
Beta
1.17
P/E (TTM)
—
P/E (Fwd)
-2.42
EPS (TTM)
$-0.14
EPS (Fwd)
$-0.55
ROE
-12.8%
ROA
-9.7%
Cash
$118.3M
Total Debt
$0
Free CF
-$27.1M
52W Change
-84.6%
Annual Financials
Cash vs Debt
Where AVXL stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, AVXL finished 55.36% below its 150-day moving average ($2.80) and 61.18% below its 200-day moving average ($3.22). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AVXL overbought or oversold?
At the October 20, 2026 close, AVXL's RSI(14) was 3.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Anavex Life Sciences Corp. reports $118.3M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$27.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -12.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Anavex Life Sciences Corp.'s trajectory.